Business Context and Reporting Period
Company: Seastar Medical Holding Corp (Nasdaq: ICU)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Seastar is a commercial-stage healthcare company developing the Selective Cytopheretic Device (SCD) to treat hyperinflammation and organ failure. The company received FDA Humanitarian Device Exemption (HDE) approval in February 2024 for its pediatric product, QUELIMMUNE, and began commercial shipments in July 2024. It is currently conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult Acute Kidney Injury (AKI).
Key Financial Metrics
| Metric ($ in thousands) | 2025 | 2024 |
|---|---|---|
| Net Revenue | $1,234 | $135 |
| Cost of Goods Sold | $53 | $0 |
| Gross Profit | $1,181 | $135 |
| Research & Development Expenses | $7,518 | $9,105 |
| General & Administrative Expenses | $5,838 | $8,872 |
| Net Loss | $(12,150) | $(24,830) |
| Cash and Cash Equivalents (End of Period) | $11,980 | $1,819 |
| Accumulated Deficit | $(151,714) | $(139,564) |
| Working Capital | $9,838 | $(3,075) |
Note: The company reported a net loss per share of $(5.86) for 2025 compared to $(66.33) for 2024. The significant improvement in loss per share is partially due to a 1-for-250 reverse stock split effective in 2024/2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 814% to $1.2 million, driven by the commercial launch of QUELIMMUNE. Customer count grew from 3 to 10 active hospital customers.
- Expense Reduction: Total operating expenses decreased 26% to $13.4 million. R&D expenses dropped 17% due to reduced consulting fees and pre-clinical costs, while G&A expenses fell 34% primarily due to the absence of 2024 restatement-related legal and accounting fees.
- Non-Operating Items: Other income/expense improved significantly from a $7.0 million loss in 2024 to a $28 thousand gain in 2025. This was largely due to the absence of a $6.1 million fair value loss on convertible notes in 2025 (notes were settled in 2024).
- Liquidity: Cash position improved from $1.8 million to $12.0 million, supported by $23.8 million in net cash provided by financing activities (equity offerings and warrant exercises).
Outlook, Risks, and Contingencies
Going Concern Warning
The company's independent auditors have issued an "emphasis of matter" paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management states that existing cash is insufficient to fund operations for the next 12 months, necessitating additional equity or debt financing.
Clinical and Regulatory Outlook
- Adult AKI Trial: The NEUTRALIZE-AKI pivotal trial is ongoing. As of March 2026, 178 of 339 patients were enrolled. Topline results and a potential Pre-market Approval (PMA) submission are anticipated in 2027.
- Pediatric Commercialization: The FDA reduced the mandatory enrollment size for the SAVE Surveillance Registry from 300 to 50 patients based on safety data. The 50th patient was enrolled in March 2026.
- Breakthrough Designations: The company holds six FDA Breakthrough Device Designations (BDD) for various indications, including adult AKI, cardiorenal syndrome, and end-stage renal disease.
Legal and Operational Risks
- Litigation: The company is defending a putative class action lawsuit (Wells v. SeaStar Medical) alleging misstatements regarding FDA approval timelines and financial restatements. A magistrate judge recommended dismissal with leave to amend in February 2026.
- Supply Chain: The company relies on single-source suppliers for critical components (cartridges) and IV solutions (calcium/citrate). Disruptions could halt clinical trials or commercial sales.
- Reimbursement: Future commercial success depends on securing third-party reimbursement (Medicare/Medicaid and private payors), which is uncertain for novel devices.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and the $12 million cash balance.
- NEUTRALIZE-AKI Enrollment: Monitor the pace of patient enrollment in the adult pivotal trial to assess the likelihood of a 2027 PMA submission.
- QUELIMMUNE Adoption: Track the number of active hospital customers and revenue per customer to validate the commercialization strategy post-distributor termination.
- Legal Status: Monitor the outcome of the Wells class action lawsuit and the magistrate judge's final ruling on the motion to dismiss.
- Supply Agreements: Review the status of the supply agreement with Fresenius USA Marketing, Inc. and the development of a second-source supplier for cartridges.